“Results from Part 1 Safety Run-in Period of a 2-Part, Phase 2, Multicenter, Open-Label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects With Basal Cell Carcinoma”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s260, https://doi.org/10.25251/skin.7.supp.260.